In the midst of COVID-19, we are all itching for some good news and a return to normalcy. There are many new neurotoxins and filler products that are expected to hit the market this year or the following year that are creating a lot of buzz in the aesthetic world. We can’t wait to get back to work and try these out for ourselves when they become available!
Restylane Kysse is a new long-lasting lip filler from Galderma recently approved by the FDA. It is a hyaluronic acid filler designed especially for the lips with a unique cross linking formulation developed specifically for sensitive lips. Therefore, it is great for a patient that has sensitive lips or is wanting a more subtle outcome. It contains local anesthetic lidocaine for improved comfort, especially with patients whose lips are sensitive to pain. It has been proven to cause minimal swelling in patients and is less prone to palpability and lumps. Additionally, Kysse was clinically proven to last 6-9 months, with some patients experiencing results for up to 12 months. This new lip filler is stirring a lot of excitement in the aesthetic world.
Daxibotulinum toxin (or DAXI) by Revance
Revance Therapeutics, INC, a biotechnology company focused on aesthetic and therapeutic offerings, has announced that the FDA has approved it’s Biologics License Application (BLA) for their new neuromodulator product, DaxibotulinumtoxinA (DAXI). DAXI is a botulinum A toxin similar to BOTOX, used for moderate to severe glabellar wrinkles and lines, or frown lines. What sets DAXI apart is that it is longer-lasting. In clinical trials, results are between 24-28 weeks. The clinical trials are actually the largest aesthetic neuromodulator clinical study conducted so far for the treatment of glabellar lines. It is not yet approved by the FDA but we hope to see it hit the market later this year or early next year. This product will also signify a major change in the aesthetic industry as there has not been a new neurotoxin like this introduced to the market in several years.
Juvederm Volux and Juvederm Volite
2020 is turning out to be the year of the golden jawline, similar to 2019. A new product from Juvederm could be a game-changer for jawline definition. Volux, which is not yet available in the U.S., is a hyaluronic acid dermal filler used for facial volume loss. It is denser than other products in the market, and is often used to sculpt the chin and jawline. Juvederm Volite, is an injectable treatment intended to improve skin quality. The main objective of this treatment is not to smooth wrinkles or lines, but to make the skin look more hydrated and improve the tone and texture of the skin.
We are excited about the new neurotoxins and fillers that may become available in the coming year. It is always exciting to expand our range of treatments available to our patients to help them with their individual needs.